{"disease":{"id":"malignant-tumor-of-stomach","name":"Malignant tumor of stomach","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":15,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Malignant tumor of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"ramucirumab","indication_name":"Malignant tumor of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyramza","generic_name":"RAMUCIRUMAB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]","quality_score":10,"revenue":"900","mechanism":"Cyramza blocks the VEGFR2 receptor, which is involved in cancer cell growth and spread."},{"drug_id":"gimeracil","indication_name":"Malignant tumor of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gimestat","generic_name":"GIMERACIL","company_name":"Nordic Group BV","drug_phase":"marketed","molecular_target":"Dihydropyrimidine dehydrogenase [NADP(+)]","drug_class":"gimeracil","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"tegafur","indication_name":"Malignant tumor of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Florafur","generic_name":"TEGAFUR","company_name":"Nordic Group BV","drug_phase":"marketed","molecular_target":"","drug_class":"tegafur","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"oxaliplatin","indication_name":"Malignant tumor of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eloxatin","generic_name":"Oxaliplatin","company_name":"Yakult Honsha","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Platinum-based chemotherapy agent","quality_score":70,"revenue":null,"mechanism":"Oxaliplatin forms platinum-DNA crosslinks that inhibit replication and transcription."},{"drug_id":"taxotere","indication_name":"Malignant tumor of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxotere","company_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"docetaxol","indication_name":"Malignant tumor of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Docetaxol","company_name":"Fudan University","drug_phase":"phase_2","molecular_target":"Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fluorouracil","indication_name":"Malignant tumor of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carac","generic_name":"fluorouracil","company_name":"Extrovis","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"tipiracil","indication_name":"Malignant tumor of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lonsurf","generic_name":"TIPIRACIL","company_name":"Taiho Oncology Inc","drug_phase":"marketed","molecular_target":"Thymidine phosphorylase","drug_class":"Nucleoside Analog Antiviral [EPC]","quality_score":50,"revenue":null,"mechanism":"Lonsurf works by inhibiting the enzyme thymidine phosphorylase, which is involved in the breakdown of certain cancer medications."},{"drug_id":"docetaxel","indication_name":"Malignant tumor of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxotere","generic_name":"Docetaxel","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Growth hormone-releasing hormone receptor","drug_class":"Microtubule Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Taxotere works by binding to microtubules, preventing them from disassembling and thereby blocking cell division."},{"drug_id":"levofolinic-acid","indication_name":"Malignant tumor of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fusilev","generic_name":"Levofolinic acid","company_name":"Spectrum Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Folate Analog","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"levoleucovorin","indication_name":"Malignant tumor of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fusilev","generic_name":"levoleucovorin","company_name":"Acrotech Biopharma","drug_phase":"marketed","molecular_target":"","drug_class":"Folate Analog","quality_score":65,"revenue":null,"mechanism":"Fusilev works by bypassing the enzyme dihydrofolate reductase, allowing normal cell growth and DNA synthesis."},{"drug_id":"5-fu","indication_name":"Malignant tumor of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carac","generic_name":"5-fu","company_name":"Spectrum Pharms","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"xeloda","indication_name":"Malignant tumor of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xeloda","company_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"capecitabine","indication_name":"Malignant tumor of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":15,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"oxaliplatin","guideline_body":"FDA label","recommendation":"Oxaliplatin Injection is indicated for the treatment of malignant tumor of the stomach, but specific details are not provided in the label.","line_of_therapy":"not specified","evidence_grade":"not specified","guideline_year":null},{"drug_id":"oxaliplatin","guideline_body":"FDA label","recommendation":"Oxaliplatin Injection is indicated for the treatment of metastasis from malignant tumor of the colon, but specific details are not provided in the label.","line_of_therapy":"not specified","evidence_grade":"not specified","guideline_year":null},{"drug_id":"oxaliplatin","guideline_body":"FDA label","recommendation":"Oxaliplatin Injection is indicated for the treatment of small intestine cancer, but specific details are not provided in the label.","line_of_therapy":"not specified","evidence_grade":"not specified","guideline_year":null},{"drug_id":"docetaxel","guideline_body":"FDA label","recommendation":"Docetaxel in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"docetaxel","guideline_body":"FDA label","recommendation":"Docetaxel in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}